Interactive Financial Charts Not Available

Eli Lilly and (LLY) | Financial Analysis & Statements

Eli Lilly and Company | Mega-cap | Healthcare

$711.66

0.26%

Eli Lilly and vs Johnson & Johnson Eli Lilly and vs AbbVie Eli Lilly and vs Merck & Co Eli Lilly and vs Amgen Eli Lilly and vs Gilead Sciences Eli Lilly and vs S&P 500 | Market

TL;DR Income Statement Balance Sheet Cash Flow Key Ratios Peer Comparison

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Latest Quarterly: Mar 2025

Income Metrics

Revenue 12.7B

Gross Profit 10.5B 82.53%

Operating Income 5.4B 42.49%

Net Income 2.8B 21.68%

EPS (Diluted) $3.06

Balance Sheet Metrics

Total Assets 89.4B

Total Liabilities 73.5B

Shareholders Equity 15.8B

Debt to Equity 4.64

Cash Flow Metrics

Operating Cash Flow 4.9B

Free Cash Flow -1.6B

Revenue & Profitability Trend

Interactive Financial Charts Not Available

This page uses interactive financial charts and dynamic data visualization tools that require JavaScript. For detailed financial analysis:

Available Financial Data:

Income statements (annual and quarterly)
Balance sheets with asset and liability details
Cash flow statements and free cash flow analysis
Key financial ratios and performance metrics
Peer comparison and industry benchmarking

All financial data is displayed in accessible table format below. Use the table headers and structure to analyze trends and compare metrics across different periods.

Eli Lilly and Income Statement From 2020 to 2024

Metric	2024	2023	2022	2021	2020
Revenue i	45.0B	34.1B	28.5B	28.3B	24.5B
Cost of Goods Sold i	8.4B	7.1B	6.6B	7.3B	5.5B
Gross Profit i	36.6B	27.0B	21.9B	21.0B	19.1B
Gross Margin % i	81.3%	79.2%	76.8%	74.2%	77.7%
Operating Expenses
Research & Development i	11.0B	9.3B	7.2B	6.9B	6.1B
Selling, General & Administrative i	8.1B	6.9B	6.1B	6.1B	5.9B
Other Operating Expenses i	-	-	-	-	-
Total Operating Expenses i	19.1B	16.3B	13.3B	13.1B	12.0B
Operating Income i	17.5B	10.8B	8.7B	7.9B	7.1B
Operating Margin % i	38.9%	31.6%	30.3%	28.0%	28.9%
Non-Operating Items
Interest Income i	175.2M	173.6M	62.8M	25.4M	33.0M
Interest Expense i	780.6M	485.9M	331.6M	339.8M	359.6M
Other Non-Operating Income	-4.2B	-3.9B	-1.6B	-1.5B	455.1M
Pre-tax Income i	12.7B	6.6B	6.8B	6.2B	7.2B
Income Tax i	2.1B	1.3B	561.6M	573.8M	1.0B
Effective Tax Rate % i	16.5%	20.1%	8.3%	9.3%	14.3%
Net Income i	10.6B	5.2B	6.2B	5.6B	6.2B
Net Margin % i	23.5%	15.4%	21.9%	19.7%	25.2%
Key Metrics
EBITDA i	19.4B	12.5B	10.2B	9.6B	8.3B
EPS (Basic) i	$11.76	$5.83	$6.57	$5.85	$6.47
EPS (Diluted) i	$11.71	$5.80	$6.57	$5.85	$6.47
Basic Shares Outstanding i	900605000	899379000	950182000	953653000	956590000
Diluted Shares Outstanding i	900605000	899379000	950182000	953653000	956590000

Income Statement Trend

Eli Lilly and Balance Sheet From 2020 to 2024

Metric	2024	2023	2022	2021	2020
Assets
Current Assets
Cash & Equivalents i	3.3B	2.8B	2.1B	3.8B	3.7B
Short-term Investments i	154.8M	109.1M	144.8M	90.1M	24.2M
Accounts Receivable i	11.0B	9.1B	6.9B	6.7B	5.9B
Inventory i	7.6B	5.8B	4.3B	3.9B	4.0B
Other Current Assets	111.4M	149.5M	7.3M	2.5B	-
Total Current Assets i	32.7B	25.7B	18.0B	18.5B	17.5B
Non-Current Assets
Property, Plant & Equipment i	11.5B	10.3B	9.4B	8.9B	8.6B
Goodwill i	17.7B	16.8B	15.4B	15.5B	15.0B
Intangible Assets i	6.2B	6.9B	7.2B	7.7B	7.4B
Long-term Investments	-	-	-	-	-
Other Non-Current Assets	13.7B	10.5B	7.1B	6.6B	6.3B
Total Non-Current Assets i	46.0B	38.3B	31.5B	30.4B	29.2B
Total Assets i	78.7B	64.0B	49.5B	48.8B	46.6B
Liabilities
Current Liabilities
Accounts Payable i	3.2B	2.6B	1.9B	1.7B	1.6B
Short-term Debt i	5.1B	6.9B	1.5B	1.5B	8.7M
Current Portion of Long-term Debt	-	-	-	-	-
Other Current Liabilities	5.1B	3.3B	2.8B	3.0B	2.8B
Total Current Liabilities i	28.4B	27.3B	17.1B	15.1B	12.5B
Non-Current Liabilities
Long-term Debt i	28.5B	18.3B	14.7B	15.3B	16.6B
Deferred Tax Liabilities i	-	-	87.3M	1.7B	2.1B
Other Non-Current Liabilities	2.2B	2.2B	1.8B	1.6B	1.7B
Total Non-Current Liabilities i	36.1B	25.8B	21.6B	24.6B	28.3B
Total Liabilities i	64.4B	53.1B	38.7B	39.7B	40.8B
Equity
Common Stock i	592.4M	593.6M	594.1M	596.3M	598.2M
Retained Earnings i	13.5B	10.3B	10.0B	9.0B	7.8B
Treasury Stock i	49.5M	44.2M	50.5M	52.7M	55.7M
Other Equity	-	-	-	-	-
Total Shareholders Equity i	14.3B	10.9B	10.8B	9.2B	5.8B
Key Metrics
Total Debt i	33.6B	25.2B	16.2B	16.9B	16.6B
Working Capital i	4.4B	-1.6B	896.3M	3.4B	5.0B

Balance Sheet Composition

Eli Lilly and Cash Flow Statement From 2020 to 2024

Metric	2024	2023	2022	2021	2020
Operating Activities
Net Income i	10.6B	5.2B	6.2B	5.6B	6.2B
Depreciation & Amortization i	1.8B	1.5B	1.5B	1.5B	1.3B
Stock-Based Compensation i	645.6M	628.5M	371.1M	342.8M	308.1M
Working Capital Changes i	-2.1B	-3.1B	-800.0K	-1.0B	-1.1B
Operating Cash Flow i	12.3B	6.1B	7.3B	7.4B	7.6B
Investing Activities
Capital Expenditures i	-5.1B	-3.4B	-1.9B	-1.3B	-1.4B
Acquisitions i	-947.7M	-1.0B	-327.2M	-747.4M	-849.3M
Investment Purchases i	-775.8M	-829.0M	-707.6M	-1.0B	-370.1M
Investment Sales i	522.5M	700.3M	463.6M	847.4M	886.8M
Investing Cash Flow i	-6.6B	-4.8B	-2.7B	-2.4B	-1.6B
Financing Activities
Share Repurchases i	-2.5B	-750.0M	-1.5B	-1.2B	-500.0M
Dividends Paid i	-4.7B	-4.1B	-3.5B	-3.1B	-2.7B
Debt Issuance i	11.4B	4.0B	0	2.4B	2.1B
Debt Repayment i	-664.2M	0	-1.6B	-1.9B	-276.5M
Financing Cash Flow i	1.2B	3.5B	-5.4B	-4.1B	-3.1B
Free Cash Flow i	414.3M	-3.2B	4.6B	5.4B	4.5B
Net Change in Cash i	7.0B	4.8B	-812.2M	808.5M	2.9B

Cash Flow Trend

Eli Lilly and Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 45.00

Forward P/E 30.45

Price to Book 33.86

Price to Sales 11.61

PEG Ratio 0.49

Profitability Ratios

Profit Margin 25.91%

Operating Margin 45.81%

Return on Equity 86.29%

Return on Assets 16.55%

Financial Health

Current Ratio 1.28

Debt to Equity 217.89

Beta 0.44

Per Share Data

EPS (TTM) $15.33

Book Value per Share $20.38

Revenue per Share $59.22

Peer Financial Comparison

Company	Market Cap	P/E Ratio	P/B Ratio	ROE	Profit Margin	Debt/Equity
lly	618.5B	45.00	33.86	86.29%	25.91%	217.89
Johnson & Johnson	428.2B	19.06	5.45	30.21%	25.00%	64.69
AbbVie	365.1B	97.94	-2,641.62	112.85%	6.45%	-511.49
Merck & Co	212.1B	13.09	4.34	35.42%	25.79%	72.16
Amgen	159.6B	24.22	21.48	99.14%	18.96%	756.65
Gilead Sciences	146.4B	23.41	7.45	33.40%	21.87%	127.34

Financial data is updated regularly. All figures are in the company's reporting currency.